Showing 3811-3820 of 4165 results for "".
- OcuTerra Completes Enrollment in Phase 2 DR:EAM Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathyhttps://modernod.com/news/ocuterra-completes-enrollment-in-phase-2-dream-trial-of-topically-delivered-ott166-in-adults-with-diabetic-retinopathy/2481732/OcuTerra Therapeutics announced full enrollment in the company’s phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe nonproliferative diabeti
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-vrdn-001-in-patients-with-chronic-thyroid-eye-disease-ted/2481716/Viridian Therapeutics announced positive preliminary data from its ongoing phase 1/2 clinical trial of VRDN-001, an investigational full antagonist antibody to the insulin-like growth factor 1 receptor (IGF-1R), in patients with chronic thyroid eye disease (TED). The company also announced an ame
- SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and Other Chronic Ophthalmic Diseaseshttps://modernod.com/news/spyglass-pharma-completes-90-million-series-c-financing-to-advance-novel-treatments-for-glaucoma-and-other-chronic-ophthalmic-diseases/2481711/SpyGlass Pharma announced the closing of $90 million in Series C financing to enable the company to conduct multiple US clinical trials of SpyGlass’ drug delivery platform. The SpyGlass system has the potential to deliver multiple years of medical therapy to address significant unmet n
- Ciliatech Presents 2-Year Postoperative Results on New Cilio-Scleral Surgical Approach for Treating Glaucomahttps://modernod.com/news/ciliatech-presents-2-year-postoperative-results-on-new-cilio-scleral-surgical-approach-for-treating-glaucoma/2481698/Ciliatech announced it will present the preliminary results of the second 2-year postoperative clinical trial (SAFARI II) on its Cilia-scleral Interposition Device (CID) during the World Glaucoma Congress, taking place this week. Ciliatech will present results showing sta
- Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)https://modernod.com/news/cigna-expands-coverage-of-glaucoma-surgical-procedures-to-include-canaloplasty-and-goniotomy-trabeculotomy/2481686/Cigna has updated its 'Glaucoma Surgical Procedure' policy to cover both ab interno canaloplasty and goniotomy (trabeculotomy) procedures for the treatment of open-angle glaucoma, effective June 15, 2023. “We are pleased that Cigna’s clinical review resulted in
- EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret in Wet AMD and DMEhttps://modernod.com/news/eyebio-announces-first-patients-dosed-in-phase-1b2-trial-of-restoret-in-wet-amd-and-dme/2481675/Eyebiotech announced the dosing of the first participants in its phase 1b/2 AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) clinical trial in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The AMARONE tria
- Ocular Therapeutix Announces 12-Month Topline Data from Ongoing Phase 1 Trial Evaluating OTX-TKI for Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-12-month-topline-data-from-ongoing-phase-1-trial-evaluating-otx-tki-for-wet-amd/2481669/Ocular Therapeutix announced 12-month data from its phase 1 US clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant, for the treatment of wet age-related macular degeneration (AMD). OTX-TKI is also being developed for the treatment of diabetic retinop
- Alimera Completes Recruitment for Its NEW DAY Study Evaluating Iluvien for DMEhttps://modernod.com/news/alimera-completes-recruitment-for-its-landmark-new-day-study/2481633/Alimera Sciences announced that it has completed enrollment for the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone acetonide intravitreal implant, 0.19mg) as a baseline therapy in p
- Sight Sciences: Two Year Study Results Show Sustained Reductions in IOP and Glaucoma Medication Use with Omni Treatmenthttps://modernod.com/news/sight-sciences-two-year-study-results-show-sustained-reductions-in-iop-and-glaucoma-medication-use-in-mild-moderate-poag-patients-treated-with-omni/2481630/Sight Sciences announced the publication of 2-year results of the ROMEO (Retrospective, Observational, Multicenter, Evaluation of OMNI) study in Clinical Ophthalmology. The longest multicenter study of the Omni Surgical System technology to date in both standalone and comb
- Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapieshttps://modernod.com/news/ray-therapeutics-closes-oversubscribed-100m-series-a-financing-to-advance-optogenetic-gene-therapies/2481621/Ray Therapeutics announced an upsized and oversubscribed $100 million Series A financing round to advance multiple programs targeting blinding diseases through clinical development. Ray Therapeutics has developed an optogenetic platform to bioengineer a pipeline of g